Tuning, Rather than Blocking, Immunity in IBD

The treatment of inflammatory bowel disease currently relies on immunosuppressive therapies that often lose effectiveness, carry infection risks, and drive high treatment cycling. Abivax is betting that fine-tuning, rather than suppressing, the immune system can reshape the treatment paradigm in IBD. Marc de Garidel, CEO of Abivax, discusses how a once-failed HIV candidate evolved into a late‑stage oral IBD therapy that may deliver durable remission, how it acts upstream of key inflammatory pathways, and its potential in a crowded but still underserved IBD market.

You can listen to Tuning, Rather than Blocking, Immunity in IBD online on Radio and Podcast. Open the player on this page to stream the available audio.

Tuning, Rather than Blocking, Immunity in IBD is an episode from The Bio Report by Levine Media Group.

This episode is 35:47 long.

This episode was published on Apr 15, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Bio Report when more episodes are available from the podcast feed.